Showing 1 - 2 results of 2 for search 'Letrent, S', query time: 0.02s Refine Results
  1. 1
    Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab.

    Dacomitinib, an irreversible Pan-ErbB inhibitor significantly abrogates growth in head and neck cancer models that exhibit low response to cetuximab. by Ferdows Ather, Habib Hamidi, Marlena S Fejzo, Stephen Letrent, Richard S Finn, Fairooz Kabbinavar, Christian Head, Steven G Wong

    Published 2013-01-01
    Get full text
    Article
  2. 2
    Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer.

    Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-c... by Ramalingam, S, Blackhall, F, Krzakowski, M, Barrios, C, Park, K, Bover, I, Seog Heo, D, Rosell, R, Talbot, D, Frank, R, Letrent, S, Ruiz-Garcia, A, Taylor, I, Liang, J, Campbell, A, O'Connell, J, Boyer, M

    Published 2012
    Journal article

Search Tools: